Overbeek JA, et al. - Using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network, researchers assessed real-world antidiabetic treatment outcomes over 12 months in obese people with type 2 diabetes mellitus (T2DM) who received oral antidiabetic therapy previously and then began a first injectable therapy with liraglutide or basal insulin. The findings of this retrospective, propensity score-matched, longitudinal cohort study in matched obese patients with T2DM demonstrated that liraglutide was more efficacious than basal insulin supported oral therapy (BOT) for glycated hemoglobin control and weight/body mass index reductions. The outcomes suggested that patients were more likely to maintain glycemic control over time after initiating liraglutide than after initiating BOT.